VistaGen Therapeutics Inc

NASDAQ:VTGN  
0.97
-0.07 (-7.03%)
Earnings Announcements

Vistagen Therapeutics Reports Fiscal Year 2022 Financial Results And Provides Corporate Update

Published: 06/23/2022 20:31 GMT
VistaGen Therapeutics Inc (VTGN) - Vistagen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update.
Vistagen Therapeutics Inc - Palisade-2 on Track for Topline Readout in Late 2022.
Vistagen Therapeutics Inc - Topline Results for Palisade-1 Anticipated Mid-2022.
Vistagen Therapeutics Inc - at March 31, 2022, Company Had Cash and Cash Equivalents of Approximately $68.1 Million.
Vistagen - Received FDA Consensus That Data From Nonclinical & Clinical Studies of Ph94b Completed to Date Provide No Signal of Abuse Potential.
Revenue is expected to be $0.21 Million
Adjusted EPS is expected to be -$0.08

Next Quarter Revenue Guidance is expected to be $0.21 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.